Neurocrine Bio. (NBIX) PT Raised to $135 at Credit Suisse
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $154.26 -0.82%
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Credit Suisse analyst Evan Seigerman raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $135.00 (from $101.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Analog Devices (ADI) PT Raised to $500 at JPMorgan
- Estee Lauder (EL) PT Raised to $112 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
